December 1, 2016 - By Marie Mckinney · 0 Comments
Dec 1 is a positive day so far for ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) as the ETF is active during the day after gaining 3.2% to hit $34.22 per share. The exchange traded fund has 70.80 million net assets and 4.60% volatility this month.
Over the course of the day 287,780 shares traded hands, as compared to an average volume of 427,580 over the last 30 days for ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS).
The ETF is -44.08% of its 52-Week High and 8.40% of its low, and is currently having ATR of 2.12. This year’s performance is 5.19% while this quarter’s performance is -2.27%.
The ETF’s YTD performance is 0%, the 1 year is 0% and the 3 year is 0%.
More notable recent ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) news were published by: Marketwatch.com which released: “ProShares UltraShort Nasdaq Biotechnology” on June 16, 2010, also Etfdailynews.com with their article: “The Best Biotech ETF To Buy and One To Avoid [iShares NASDAQ Biotechnology …” published on October 14, 2014, Nasdaq.com published: “The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International …” on September 30, 2015. More interesting news about ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) were released by: Seekingalpha.com and their article: “Biotech Strategy Following Brexit: Run, Don’t Walk” published on June 27, 2016 as well as Benzinga.com‘s news article titled: “ProShares Releases 2 New Leveraged Biotech ETFs” with publication date: June 23, 2015.
ProShares Ultra Nasdaq Biotechnology seeks investment results for a single day only, not for longer periods. The company has a market cap of $70.80 million. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. It currently has negative earnings. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marie Mckinney